Journal
Evidence literacy and regulatory context for reading the atlas without turning uncertain research into clinical claims.
Building a 100-peptide evidence atlas — the meta story
How 100 monographs and a source-traceable methodology became an evidence-first research atlas — different from a product directory.
Evidence grades A to E explained — and when X applies
How the atlas assigns A through E (and X) to indication-specific claims, with worked examples from three monographs.
How peptide identity is verified — sequences, structures, and caveats
How the atlas resolves sequences, PubChem structures, salts, conjugates, mixtures, and ambiguous entries for each catalog peptide.
How to read a peptide clinical trial — study-level fields decoded
A field-by-field guide to the Key studies and Evidence-by-claim tables that power each Peptidepedia monograph.
How to read peptide evidence without outrunning it
A practical guide to evidence grades, claim tables, regulatory status, and verification dates across the Peptidepedia atlas.
Peptide blend names decoded: what GLOW, Wolverine, and KLOW really mean
Peptide blend names like GLOW and Wolverine vary in composition, lack regulatory standards, and have no combination-specific evidence.
Peptide regulation: a world tour of four approaches
How the United States, European Union, United Kingdom, and Canada regulate peptides—contrasting FDA, EMA, MHRA, and Health Canada approaches.
Research market versus approved peptides — reading the entry types
Why the atlas distinguishes approved drugs, investigational candidates, endogenous peptides, research-market products, and boundary cases.
WADA, sport, and peptides: navigating the Prohibited List
How the WADA Prohibited List classifies peptides under categories S0, S2, and S4—with examples from the peptide atlas.
Why peptide stability and cold chain matter — concepts for evidence literacy
The science behind lyophilization, glass-transition temperature, cold-chain integrity, and why product quality varies outside regulated conditions.